LABD stock forecast, quote, news & analysis

Key Takeaways

• LABD has surged approximately 17% over the past 30 days, recovering from a multi-year low of $6.86 reached on July 9 to trade near $9.28.
• The move was primarily driven by a sharp pullback in the S&P Biotechnology Select Industry Index, which reversed after an extended rally through June and early July.
• Over the broader quarter, LABD remains down roughly 31%, reflecting the powerful biotech sector rally that dominated from late May through early July.
• Profit-taking across small- and mid-cap biotech names, combined with mixed second-quarter earnings results, triggered the index reversal that benefited this inverse leveraged ETF (Exchange-Traded Fund).
• As a -3x daily inverse fund, LABD magnifies short-term moves in the underlying index, making it highly sensitive to sudden shifts in biotech sentiment.
• Strong M&A (mergers and acquisitions) activity and a robust biotech IPO market continue to shape the sector backdrop, creating both opportunities and risks for inverse positioning.

Direxion Daily S&P Biotech Bear 3X Shares (LABD) Overview and Portfolio Exposure

LABD is a leveraged inverse ETF that seeks to deliver -300% of the daily return of the S&P Biotechnology Select Industry Index, before fees and expenses. The fund, launched in May 2015 and managed by Direxion, uses swap agreements, futures contracts, and short positions to achieve its daily inverse exposure目标. The underlying index is an equal-weighted benchmark comprising US-listed biotechnology companies spanning the small-, mid-, and large-cap spectrum. Notable constituents include Apogee Therapeutics (APGE), Moderna (MRNA), Viking Therapeutics (VKTX), Twist Bioscience (TWST), and Kymera Therapeutics (KYMR), each representing approximately 1.3% to 1.6% of the index. LABD itself holds approximately 12 positions, predominantly cash instruments and swap agreements, and carries a net expense ratio of 1.07%. Because it resets daily, the fund is designed for short-term tactical positioning rather than buy-and-hold strategies.

LABD Price Performance: Last 30 Days vs. Quarter

During the last 30 days, LABD climbed approximately 17%, moving from a closing price of $7.95 on July 1 to an intraday level near $9.28 on July 31. The rebound was not linear: the ETF hit a trough of $6.86 on July 9 before reversing sharply higher. Over the last quarter, the picture is markedly different. LABD has declined approximately 31%, falling from roughly $13.42 in late May to current levels, as the underlying biotech index staged a sustained rally through June and into early July. This divergence between the 30-day recovery and the quarterly decline illustrates the amplified, trend-sensitive nature of leveraged inverse products.

What Drove LABD Price in the Last 30 Days

The primary catalyst behind LABD's 17% gain was a meaningful pullback in the S&P Biotechnology Select Industry Index. Through June and the first week of July, biotech stocks extended a powerful rally fueled by a surge in IPO activity, blockbuster M&A transactions, and improving clinical trial data. The Nasdaq Biotechnology Index had gained approximately 13% year-to-date, and biotech IPOs delivered a weighted average return of 55%, far outpacing the broader US IPO market. This relentless uptrend pushed LABD to its lowest level in years by July 9.

The reversal arrived swiftly. On July 10, the underlying biotech index dropped roughly 3.2% in a single session, triggering a 9.5% single-day spike in LABD as the -3x leverage amplified the move. Profit-taking accelerated as investors rotated away from richly valued small- and mid-cap biotech names that had led the rally. Mixed second-quarter earnings results from the healthcare sector, combined with broader macroeconomic uncertainty and the approach of a seasonally quieter August period, prompted further repositioning. Several large-cap biopharma companies, including AbbVie (ABBV) and Bristol Myers Squibb (BMY), reported solid quarterly results, but the equal-weighted nature of the underlying index meant that mid- and small-cap weakness disproportionately affected the benchmark, amplifying gains for the inverse fund.

What Drove LABD Performance Over the Last Quarter

The quarterly decline of approximately 31% reflects the strength of the biotech sector's multi-month advance rather than any single event. The S&P Biotechnology Select Industry Index climbed from around 10,300 in early June to above 13,100 by early July, driven by structural tailwinds. Biotech IPOs raised over $5 billion in proceeds during the first half of 2026, roughly triple the prior year's total, while M&A activity reached $106 billion across 201 deals in the same period. Three transactions valued at $10 billion or more were announced within a single month, including AbbVie's acquisition of Apogee Therapeutics and GSK's (GSK) purchase of Nuvalent. This deal-making returned substantial capital to healthcare-focused investors, reinforcing the sector's momentum. Additionally, a more stable regulatory environment and notable clinical breakthroughs supported risk appetite, creating sustained headwinds for LABD throughout most of the quarter.

AI Screener

Identifying ETFs and stocks that align with evolving market conditions can be challenging without the right analytical tools. Tickeron's AI Screener is an AI-powered discovery platform that enables investors to scan thousands of securities using a broad array of criteria, including technical indicators, fundamental metrics, volatility measures, AI-generated trading signals, price pattern recognition, and industry-specific filters. The screener helps users surface trending securities, breakout candidates, and new opportunities with greater efficiency than traditional manual screening. For investors monitoring leveraged and inverse ETFs such as LABD, the platform provides a streamlined way to identify shifts in sector momentum, evaluate underlying index constituents, and stay ahead of rapidly changing market dynamics.

LABD ETF Outlook: What Investors Should Watch Next

Going forward, several factors are likely to influence LABD's trajectory. The direction of the S&P Biotechnology Select Industry Index will remain the dominant driver, and that index's fate hinges on whether the biotech sector's structural tailwinds—robust IPO demand, active M&A pipelines, and positive clinical data flow—can resume their upward momentum or whether the recent pullback marks the start of a broader correction. Second-quarter earnings results from mid-cap biotech names due in early August will be closely watched for signs of pipeline progress and revenue growth. On the macroeconomic front, interest rate expectations and inflation trends will matter: higher rates have historically pressured biotech valuations, and any hawkish shift from the Federal Reserve could weigh on the sector, potentially benefiting inverse positioning. Conversely, continued strong capital flows into healthcare and further large-scale M&A announcements could reignite biotech buying and create renewed headwinds for LABD. Investors should also monitor the sharp daily compounding effects inherent to leveraged inverse products, which can cause returns to deviate significantly from simple -3x expectations over holding periods longer than a single trading session.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations